161 related articles for article (PubMed ID: 19797958)
1. Skin reactions to the new biologic anticancer drugs.
Myskowski PL; Halpern AC
Curr Opin Support Palliat Care; 2009 Dec; 3(4):294-9. PubMed ID: 19797958
[TBL] [Abstract][Full Text] [Related]
2. Review: side effects of approved molecular targeted therapies in solid cancers.
Widakowich C; de Castro G; de Azambuja E; Dinh P; Awada A
Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies: a new generation of cancer treatments.
Gerber DE
Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
6. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.
Choi JN
Clin Dermatol; 2011; 29(6):587-601. PubMed ID: 22014981
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
13. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
15. Skin toxicity of anti-cancer therapy.
Ulrich J; Hartmann JT; Dörr W; Ugurel S
J Dtsch Dermatol Ges; 2008 Nov; 6(11):959-77. PubMed ID: 18992037
[TBL] [Abstract][Full Text] [Related]
16. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
de Castro G; Awada A
Curr Opin Oncol; 2006 Jul; 18(4):307-15. PubMed ID: 16721122
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous side effects of inhibition of VEGF signal transduction.
Wozel G; Sticherling M; Schön MP
J Dtsch Dermatol Ges; 2010 Apr; 8(4):243-9. PubMed ID: 19832927
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
19. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
20. Evolving concepts in the systemic drug therapy of breast cancer.
Norton L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
